These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23332713)

  • 21. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
    Tillotson GS; Echols RM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulating Antibiotics in an Era of Resistance: The Historical Basis and Continued Need for Adequate and Well-Controlled Investigations.
    Podolsky SH; Powers JH
    Ann Intern Med; 2015 Sep; 163(5):386-8. PubMed ID: 26167660
    [No Abstract]   [Full Text] [Related]  

  • 23. The future of antibiotics.
    Spellberg B
    Crit Care; 2014 Jun; 18(3):228. PubMed ID: 25043962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia.
    Kudrin A
    J Clin Pharmacol; 2009 Mar; 49(3):268-80. PubMed ID: 19168433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance.
    Finch R;
    J Antimicrob Chemother; 2011 Sep; 66(9):1945-7. PubMed ID: 21700629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trials and tribulations of antibiotic development.
    Lancet Infect Dis; 2008 Apr; 8(4):209. PubMed ID: 18353256
    [No Abstract]   [Full Text] [Related]  

  • 28. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000--why aren't we doing better?
    Garazzino S; Lutsar I; Bertaina C; Tovo PA; Sharland M
    Int J Antimicrob Agents; 2013 Aug; 42(2):99-118. PubMed ID: 23810180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR;
    J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active controlled studies in antibiotic drug development.
    Dane A
    Pharm Stat; 2011; 10(5):454-60. PubMed ID: 21956949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nature's clarion call of antibacterial resistance: are we listening?
    Theuretzbacher U; Toney JH
    Curr Opin Investig Drugs; 2006 Feb; 7(2):158-66. PubMed ID: 16499286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibacterial drug discovery: is it all downhill from here?
    Projan SJ; Shlaes DM
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel heterodimer antibiotics: a review of recent patent literature.
    Long DD; Marquess DG
    Future Med Chem; 2009 Sep; 1(6):1037-50. PubMed ID: 21425993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The global need for effective antibiotics-moving towards concerted action.
    Cars O; Hedin A; Heddini A
    Drug Resist Updat; 2011 Apr; 14(2):68-9. PubMed ID: 21444235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The United States Food and Drug Administration and the end of antibiotics.
    Shlaes DM; Moellering RC
    Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094
    [No Abstract]   [Full Text] [Related]  

  • 40. The global need for effective antibiotics: challenges and recent advances.
    Högberg LD; Heddini A; Cars O
    Trends Pharmacol Sci; 2010 Nov; 31(11):509-15. PubMed ID: 20843562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.